These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals. Wang C; Cai Y; Gu Z; Ma J; Zheng Z; Tang BS; Xu Y; Zhou Y; Feng T; Wang T; Chen SD; Chan P; Neurobiol Aging; 2014 Mar; 35(3):725.e1-6. PubMed ID: 24095219 [TBL] [Abstract][Full Text] [Related]
26. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease. Pang SY; Lo RCN; Ho PW; Liu HF; Chang EES; Leung CT; Malki Y; Choi ZY; Wong WY; Kung MH; Ramsden DB; Ho SL Transl Neurodegener; 2022 Jan; 11(1):5. PubMed ID: 35101134 [TBL] [Abstract][Full Text] [Related]
27. LRRK2, GBA and SMPD1 Founder Mutations and Parkinson's Disease in Ashkenazi Jews. Dagan E; Schlesinger I; Kurolap A; Ayoub M; Nassar M; Peretz-Aharon J; Gershoni-Baruch R Dement Geriatr Cogn Disord; 2016; 42(1-2):1-6. PubMed ID: 27449028 [TBL] [Abstract][Full Text] [Related]
28. LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease. Gan-Or Z; Bar-Shira A; Mirelman A; Gurevich T; Kedmi M; Giladi N; Orr-Urtreger A Neurogenetics; 2010 Feb; 11(1):121-5. PubMed ID: 19458969 [TBL] [Abstract][Full Text] [Related]
29. Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene. Thaler A; Bregman N; Gurevich T; Shiner T; Dror Y; Zmira O; Gan-Or Z; Bar-Shira A; Gana-Weisz M; Orr-Urtreger A; Giladi N; Mirelman A Parkinsonism Relat Disord; 2018 Oct; 55():45-49. PubMed ID: 29784561 [TBL] [Abstract][Full Text] [Related]
30. Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal. von Linstow CU; Gan-Or Z; Brundin P Transl Neurodegener; 2020 Oct; 9(1):39. PubMed ID: 33066808 [TBL] [Abstract][Full Text] [Related]
31. Clinical Features of LRRK2 Carriers with Parkinson's Disease. Kestenbaum M; Alcalay RN Adv Neurobiol; 2017; 14():31-48. PubMed ID: 28353277 [TBL] [Abstract][Full Text] [Related]
32. New therapeutic approaches to Parkinson's disease targeting GBA, LRRK2 and Parkin. Senkevich K; Rudakou U; Gan-Or Z Neuropharmacology; 2022 Jan; 202():108822. PubMed ID: 34626666 [TBL] [Abstract][Full Text] [Related]
33. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls. Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023 [TBL] [Abstract][Full Text] [Related]
34. Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers. Pont-Sunyer C; Iranzo A; Gaig C; Fernández-Arcos A; Vilas D; Valldeoriola F; Compta Y; Fernández-Santiago R; Fernández M; Bayés A; Calopa M; Casquero P; de Fàbregues O; Jaumà S; Puente V; Salamero M; José Martí M; Santamaría J; Tolosa E PLoS One; 2015; 10(7):e0132368. PubMed ID: 26177462 [TBL] [Abstract][Full Text] [Related]
35. Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell Line. Ruz C; Alcantud JL; Vives F; Arrebola F; Hardy J; Lewis PA; Manzoni C; Duran R Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805938 [TBL] [Abstract][Full Text] [Related]
36. Alpha galactosidase A activity in Parkinson's disease. Alcalay RN; Wolf P; Levy OA; Kang UJ; Waters C; Fahn S; Ford B; Kuo SH; Vanegas N; Shah H; Liong C; Narayan S; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Oliva P; Keutzer J; Marder K; Zhang XK Neurobiol Dis; 2018 Apr; 112():85-90. PubMed ID: 29369793 [TBL] [Abstract][Full Text] [Related]
37. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study. Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161 [TBL] [Abstract][Full Text] [Related]
38. Genetic heterogeneity on sleep disorders in Parkinson's disease: a systematic review and meta-analysis. Huang J; Cheng Y; Li C; Shang H Transl Neurodegener; 2022 Apr; 11(1):21. PubMed ID: 35395825 [TBL] [Abstract][Full Text] [Related]
39. Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants. Zhang L; Quadri M; Guedes LC; Coelho M; Valadas A; Mestre T; Lobo PP; Rosa MM; Simons E; Oostra BA; Ferreira JJ; Bonifati V Parkinsonism Relat Disord; 2013 Oct; 19(10):897-900. PubMed ID: 23726462 [TBL] [Abstract][Full Text] [Related]
40. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease. Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]